ARCHIVES

Alimta Reduces Risk Of Progression In Patients Aged 70 Years or Older

This article is from The Cancer Letter archive.

Vol. 34 No. 10 | October 28, 2011

Download PDF Visit The Full Archive

Related Articles

Phase II Study Cohort Fails To Overcome Erlotinib Resistance

April 26, 2013

FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says.

January 14, 2005

Book By Clinical Researcher Makes Case For Nationwide Reforms

July 30, 1993

Phase III Trial Would Give Clearer Picture Of C225 Role.

February 15, 2002

CCIRC Starts Preparing For Clinical Research Review; To Include Group Achievements, Problems

March 3, 1978

Avastin Combination Approved For Metastatic Colorectal Cancer

February 22, 2013